Wada H, Kumeda Y, Ogasawara Z, Ohiwa M, Kaneko T, Tamaki S, Ohno T, Kageyama S, Kobayashi T, Deguchi K
Second Department of Internal Medicine, Mie University School of Medicine, Japan.
Am J Hematol. 1993 Feb;42(2):166-70. doi: 10.1002/ajh.2830420205.
Plasminogen activator (PA) and PA inhibitor (PAI) were measured in homogenates of leukemia cells. Both PA and PAI levels were higher in non-lymphoblastic leukemia than in lymphoblastic leukemia. The levels were below the sensitivity of determination in chronic myelocytic leukemia (CML) but showed significant increases in blast crisis (CML,bc). The level of the tissue type PA (t-PA) antigen was highest in acute myeloblastic leukemia (AML) and that of the urokinase type PA (u-PA) was highest in acute promyelocytic leukemia (APL). The PAI-I antigen showed no marked cell specificity, but the PAI-II antigen was markedly increased in myelomonocytic leukemia and acute monocytic leukemia (AMoL). From these findings, various PAs and PAIs are considered to be present in leukemia cells and to be involved in hemostatic disorders, thus they are of diagnostic value in leukemia.
在白血病细胞匀浆中检测纤溶酶原激活物(PA)和PA抑制剂(PAI)。非淋巴细胞白血病中PA和PAI的水平均高于淋巴细胞白血病。慢性粒细胞白血病(CML)中的水平低于检测灵敏度,但在急变期(CML,bc)显著升高。组织型PA(t-PA)抗原水平在急性髓细胞白血病(AML)中最高,尿激酶型PA(u-PA)水平在急性早幼粒细胞白血病(APL)中最高。PAI-1抗原无明显细胞特异性,但PAI-2抗原在粒单核细胞白血病和急性单核细胞白血病(AMoL)中显著升高。根据这些发现,认为白血病细胞中存在多种PA和PAI,并参与止血障碍,因此它们在白血病诊断中具有价值。